Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$14.80
-0.14-0.94%
At close: -
$14.80
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Ardent Health Partners Analyst Ratings and Price Targets | NYSE:ARDT | Benzinga
Ardent Health Partners Inc has a consensus price target of $21 based on the ratings of 15 analysts. The high is $25 issued by Leerink Partners on November 12, 2024. The low is $18 issued by Guggenheim on May 9, 2025. The 3 most-recent analyst ratings were released by Stephens & Co., RBC Capital, and Guggenheim on May 20, 2025, May 15, 2025, and May 9, 2025, respectively. With an average price target of $20 between Stephens & Co., RBC Capital, and Guggenheim, there's an implied 35.14% upside for Ardent Health Partners Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
RBC Capital
Guggenheim
Mizuho
Stephens & Co.
1calculated from analyst ratings
Analyst Ratings for Ardent Health Partners
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2025 | Buy Now | 41.89% | Stephens & Co. | Scott Fidel 71% | $21 → $21 | Reiterates | Overweight → Overweight | Get Alert |
| 05/15/2025 | Buy Now | 41.89% | RBC Capital | Ben Hendrix61% | $21 → $21 | Reiterates | Outperform → Outperform | Get Alert |
| 05/09/2025 | Buy Now | 21.62% | Guggenheim | Jason Cassorla52% | $16 → $18 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | 8.11% | Guggenheim | Jason Cassorla52% | → $16 | Initiates | → Buy | Get Alert |
| 04/09/2025 | Buy Now | 21.62% | Mizuho | Ann Hynes85% | $19 → $18 | Maintains | Outperform | Get Alert |
| 04/01/2025 | Buy Now | 48.65% | Stephens & Co. | Scott Fidel 71% | $22 → $22 | Reiterates | Overweight → Overweight | Get Alert |
| 03/26/2025 | Buy Now | 48.65% | Stephens & Co. | Scott Fidel 71% | $22 → $22 | Reiterates | Overweight → Overweight | Get Alert |
| 03/04/2025 | Buy Now | 41.89% | RBC Capital | Ben Hendrix61% | $23 → $21 | Maintains | Outperform | Get Alert |
| 02/27/2025 | Buy Now | 48.65% | Stephens & Co. | Raj Kumar 64% | $22 → $22 | Reiterates | Overweight → Overweight | Get Alert |
| 01/21/2025 | Buy Now | 48.65% | Morgan Stanley | Craig Hettenbach59% | $23.5 → $22 | Maintains | Overweight | Get Alert |
| 01/06/2025 | Buy Now | 41.89% | Truist Securities | David Macdonald68% | $22 → $21 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 35.14% | JP Morgan | Benjamin Rossi67% | → $20 | Assumes | → Neutral | Get Alert |
| 11/14/2024 | Buy Now | 55.41% | RBC Capital | Ben Hendrix61% | $23 → $23 | Reiterates | Outperform → Outperform | Get Alert |
| 11/12/2024 | Buy Now | 68.92% | Leerink Partners | Whit Mayo67% | $23 → $25 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 28.38% | B of A Securities | Kevin Fischbeck67% | $22 → $19 | Downgrade | Buy → Neutral | Get Alert |
| 10/11/2024 | Buy Now | 62.16% | Keybanc | Matthew Gillmor68% | → $24 | Initiates | → Overweight | Get Alert |
| 09/19/2024 | Buy Now | 62.16% | Stephens & Co. | Scott Fidel69% | $24 → $24 | Reiterates | Overweight → Overweight | Get Alert |
| 08/16/2024 | Buy Now | 48.65% | Truist Securities | David Macdonald68% | $21 → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 41.89% | Loop Capital | Timothy Greaves44% | $18 → $21 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | 62.16% | Stephens & Co. | Scott Fidel69% | $24 → $24 | Reiterates | Overweight → Overweight | Get Alert |
| 08/12/2024 | Buy Now | 48.65% | B of A Securities | Kevin Fischbeck67% | → $22 | Initiates | → Buy | Get Alert |
| 08/12/2024 | Buy Now | 55.41% | RBC Capital | Ben Hendrix61% | → $23 | Initiates | → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 41.89% | Citigroup | — | → $21 | Initiates | → Buy | Get Alert |
| 08/12/2024 | Buy Now | 21.62% | Loop Capital | Timothy Greaves44% | → $18 | Initiates | → Buy | Get Alert |
| 08/12/2024 | Buy Now | 55.41% | Leerink Partners | Whit Mayo67% | → $23 | Initiates | → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 21.62% | JP Morgan | Lisa Gill56% | → $18 | Initiates | → Neutral | Get Alert |
| 08/12/2024 | Buy Now | 41.89% | Truist Securities | David Macdonald68% | → $21 | Initiates | → Buy | Get Alert |
| 08/12/2024 | Buy Now | 35.14% | Mizuho | Ann Hynes85% | → $20 | Initiates | → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 82.43% | Morgan Stanley | Craig Hettenbach59% | → $27 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Ardent Health Partners (ARDT) stock?
The latest price target for Ardent Health Partners (NYSE:ARDT) was reported by Stephens & Co. on May 20, 2025. The analyst firm set a price target for $21.00 expecting ARDT to rise to within 12 months (a possible 41.89% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ardent Health Partners (ARDT)?
The latest analyst rating for Ardent Health Partners (NYSE:ARDT) was provided by Stephens & Co., and Ardent Health Partners reiterated their overweight rating.
When was the last upgrade for Ardent Health Partners (ARDT)?
There is no last upgrade for Ardent Health Partners
When was the last downgrade for Ardent Health Partners (ARDT)?
The last downgrade for Ardent Health Partners Inc happened on November 6, 2024 when B of A Securities changed their price target from $22 to $19 for Ardent Health Partners Inc.
When is the next analyst rating going to be posted or updated for Ardent Health Partners (ARDT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ardent Health Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ardent Health Partners was filed on May 20, 2025 so you should expect the next rating to be made available sometime around May 20, 2026.
Is the Analyst Rating Ardent Health Partners (ARDT) correct?
While ratings are subjective and will change, the latest Ardent Health Partners (ARDT) rating was a reiterated with a price target of $21.00 to $21.00. The current price Ardent Health Partners (ARDT) is trading at is $14.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
